Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Primary Objectives: * Phase I: To determine the safety, tolerability, and Phase II recommended dose of the combination of extended schedule TMZ and DAC. * Phase II: To determine the efficacy, as measured by overall response rate, of the combination of extended schedule TMZ and DAC given at the Phase II recommended dose to patients with metastatic melanoma. Secondary Objectives: * To determine pharmacokinetics of the combination of TMZ and DAC in patients with metastatic melanoma. * To determine, in peripheral blood mononuclear cells (PBMC) and tumor tissue, the pharmacodynamic effects of the combination of TMZ and DAC on promoter methylation and expression of selected genes and correlate these with response. * To determine the progression-free survival of patients treated with the combination of TMZ and DAC.